Total Funding
33
35
Total FundingPost-IPO Equity raised
Growth Score 33 in past quarter
-3 pts
Heat Score 35 in past quarter
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
208376
Arch Therapeutics is a medical device company offering an innovative therapeutic approach to stasis and barrier applications.
Richard E. Davis: Chief Financial OfficerPast Role: NMT Medical, Chairman, President and CEO- Rutledge Ellis-Behnke: Co-Founder & Scientific Advisor
About the Company
Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for
patients.
